MX2019004215A - Insercion de genes dirigida para terapia de celulas inmunes mejorada. - Google Patents

Insercion de genes dirigida para terapia de celulas inmunes mejorada.

Info

Publication number
MX2019004215A
MX2019004215A MX2019004215A MX2019004215A MX2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A
Authority
MX
Mexico
Prior art keywords
immune cells
targeted gene
gene insertion
improved immune
coding sequences
Prior art date
Application number
MX2019004215A
Other languages
English (en)
Spanish (es)
Inventor
Busser Brian
Duchateau Philippe
Juillerat Alexandre
Poirot Laurent
Valton Julien
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Priority claimed from PCT/EP2017/076798 external-priority patent/WO2018073391A1/en
Publication of MX2019004215A publication Critical patent/MX2019004215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2019004215A 2016-10-19 2017-10-19 Insercion de genes dirigida para terapia de celulas inmunes mejorada. MX2019004215A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410187P 2016-10-19 2016-10-19
DKPA201670840 2016-10-27
PCT/EP2017/076798 WO2018073391A1 (en) 2016-10-19 2017-10-19 Targeted gene insertion for improved immune cells therapy

Publications (1)

Publication Number Publication Date
MX2019004215A true MX2019004215A (es) 2019-08-21

Family

ID=60268351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004215A MX2019004215A (es) 2016-10-19 2017-10-19 Insercion de genes dirigida para terapia de celulas inmunes mejorada.

Country Status (10)

Country Link
US (3) US11873511B2 (cg-RX-API-DMAC10.html)
EP (1) EP3529351A1 (cg-RX-API-DMAC10.html)
JP (1) JP7274416B2 (cg-RX-API-DMAC10.html)
KR (1) KR102709329B1 (cg-RX-API-DMAC10.html)
CN (1) CN110023490B (cg-RX-API-DMAC10.html)
AU (1) AU2017347637B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019007715A2 (cg-RX-API-DMAC10.html)
CA (1) CA3040048A1 (cg-RX-API-DMAC10.html)
IL (1) IL265953B2 (cg-RX-API-DMAC10.html)
MX (1) MX2019004215A (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
CN110841058B (zh) * 2019-11-21 2022-09-02 北京启辰生生物科技有限公司 用于协同改善免疫应答的组合物及应用
CN110790842B (zh) * 2019-11-25 2021-03-30 贵州康钦承平生物科技有限公司 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用
EP4171616A1 (en) * 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
KR102491095B1 (ko) * 2021-01-22 2023-01-20 한국생명공학연구원 Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도
KR102500873B1 (ko) * 2021-02-03 2023-02-17 한국과학기술연구원 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도
WO2022242700A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified nk cells and uses thereof
EP4341300A1 (en) * 2021-05-21 2024-03-27 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CN113604437A (zh) * 2021-08-13 2021-11-05 青岛华赛伯曼医学细胞生物有限公司 过表达ccr2的免疫细胞及其应用
US20250319144A1 (en) * 2021-11-19 2025-10-16 Nankai University Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy
JP2025524921A (ja) * 2022-07-29 2025-08-01 レジェンド バイオテック アイルランド リミテッド 細胞療法の持続性を促進するための方法
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
CN115286697B (zh) * 2022-09-29 2022-12-13 烟台蓝纳成生物技术有限公司 一种双重靶向化合物及其制备方法和应用
CN115851909B (zh) * 2022-11-21 2023-09-08 郑州大学第一附属医院 检测fosb基因的试剂在制备诊断腹主动脉瘤产品的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CA2912375C (en) * 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
JP6608807B2 (ja) * 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
JP6976058B2 (ja) 2013-11-22 2021-12-01 セレクティスCellectis 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
US20190024065A1 (en) 2015-02-06 2019-01-24 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
BR112017020750A2 (en) * 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
EP4339287A3 (en) * 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
KR102614675B1 (ko) * 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법

Also Published As

Publication number Publication date
IL265953B2 (en) 2026-05-01
AU2017347637B2 (en) 2024-02-15
EP3529351A1 (en) 2019-08-28
CN110023490B (zh) 2024-08-09
KR102709329B1 (ko) 2024-09-23
JP7274416B2 (ja) 2023-05-16
US11873511B2 (en) 2024-01-16
US20200224163A1 (en) 2020-07-16
CN110023490A (zh) 2019-07-16
IL265953A (en) 2019-05-30
US20260103694A1 (en) 2026-04-16
RU2019113911A3 (cg-RX-API-DMAC10.html) 2021-06-28
BR112019007715A2 (pt) 2019-07-09
IL265953B1 (en) 2026-01-01
RU2019113911A (ru) 2020-11-20
US12391933B2 (en) 2025-08-19
AU2017347637A1 (en) 2019-05-02
KR20190065397A (ko) 2019-06-11
CA3040048A1 (en) 2018-04-26
US20240141293A1 (en) 2024-05-02
JP2019531743A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
MX2020004444A (es) Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.
BR112019007715A2 (pt) inserção vetorizada de genes para terapia aprimorada com células imunes
ZA201904311B (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
IL276844A (en) Interferon gene stimulator agonists and their uses
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
PL3704230T3 (pl) Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
MX2025009055A (es) Vectores de neoantigeno de alfavirus
PH12019501959A1 (en) Therapeutic rna
MX2017014469A (es) Constructos de expresion y metodos para diseñar geneticamente levadura metilotrofica.
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
CY1125996T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MX2016014129A (es) Composiciones para el control de mosquitos y usos de las mismas.
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
HUE056871T2 (hu) RNS az autoimmun betegségek kezelésére
MX2017000658A (es) Citomegalovirus humano compuesto por antígenos exógenos.
EA201892820A1 (ru) Способ стабилизации белков
EP3242930A4 (en) MICROFLUIDIC CELL CULTURE OF TUMOR CELL SPHEROIDS FROM PATIENTS
EP3867393A4 (en) Enzymatic production of tagatose
MX2021008663A (es) Anticuerpos mejorados contra il-6.
SG11202008102VA (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)